drugset / Trial / NCT00986531

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

NCT00986531

Phase 1 Completed 59 enrolled AstraZeneca
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Timeline

Start
2009-11
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8529 Other / unclassified 80 mg Oral

Indications